Accessibility Menu
ImmuPharma Plc logo

ImmuPharma Plc(LSE) IMM

Market Cap£23.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-93%
5 Year-55%
1 Year+78%
1 Month-1%
£0.04
-17.78%
-0.01Today
ImmuPharma Plc last closing stock price
MetricPriceDate
Last closeGBX 3.702026-07-30
ImmuPharma Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.5%GBX 4.002026-07-23
1 month-1.07%GBX 3.742026-06-30
3 month-10.63%GBX 4.142026-05-01
Year to date-40.32%GBX 6.202025-12-31
1 year+77.88%GBX 2.082025-07-30
3 year+60.87%GBX 2.302023-07-31
5 year-54.6%GBX 8.152021-07-30
Since inception-93.02%GBX 0.532006-02-22

ImmuPharma Plc Financials at a Glance

Market Cap

£23.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£1.81M

EPS (TTM)

-£0.00

P/E Ratio

-9.74

Dividend

£0.00

Beta (Volatility)

-0.15 (Low)

Price

£0.04

Volume

1,170,829

Open

£0.04

Previous Close

£0.04

Daily Range

£0.04 - £0.04

52-Week Range

£0.01 - £0.19

Estimated Earnings Date

Sep 24, 2026

IMM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ImmuPharma Plc

ImmuPharma PLC is a biopharmaceutical company based in the United Kingdom, specializing in the discovery and development of peptide-based therapeutics. The company focuses on addressing unmet medical needs in the areas of autoimmunity, inflammation, and anti-infectives.

Products and Services
  • P140, a peptide technology platform in Phase III trials for systemic lupus erythematosus
  • BioAMB, a peptide-based drug for serious fungal infections
  • Collaboration with Centre National de la Recherche Scientifique for the 1P40 platform
Growth Outlook
  • Ongoing Phase III trials for P140 may lead to significant market opportunities
  • Expansion into rare autoimmune disorders with P140 in Phase II trials
  • Potential partnerships could enhance product development and market reach
Financial Highlights
  • Recent quarterly net income of £31,214 indicates potential for recovery
  • Cash and cash equivalents of £1,352,249 provide operational stability
  • Trailing twelve months (TTM) revenue remains at £0, highlighting growth potential
ImmuPharma PLC is positioned in a promising sector with its innovative peptide-based therapeutics. The company’s lead product, P140, is undergoing critical clinical trials that could pave the way for future revenue streams. The focus on rare autoimmune diseases and serious infections aligns with current healthcare trends, potentially attracting interest from investors looking for growth in the biotechnology sector. The financial position, while currently showing no revenue, is supported by a solid cash reserve, allowing for continued research and development efforts. As the company progresses through its clinical trials, it may present significant opportunities for growth and value creation in the biopharmaceutical market.
AI Generated • Jul 14, 2026

Industry

Pharmaceuticals

Sector

Health Care

CEO

Tim McCarthy McCarthy, MBA

Website

www.immupharma.com

Headquarters

London, GL EC1A 7BL, GB

IMM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-353.21%

Return on Capital

-370.19%

Return on Assets

-96.20%

Earnings Yield

-10.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£23.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

623.91M

Volume

1.17M

Avg. Volume

1.87M

Financials (TTM)

Gross Profit

-£35.30K

Operating Income

-£2.54M

EBITDA

-£3.15M

Operating Cash Flow

-£3.05M

Capital Expenditure

-£2.48K

Free Cash Flow

-£3.05M

Cash & ST Invst.

£1.35M

Total Debt

£0.00

ImmuPharma Plc Performance Analysis

ImmuPharma Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 0N/A
20232023-12-31GBP 0N/A
20242024-12-31GBP 0N/A
20252025-12-31GBP 0N/A
ImmuPharma Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
ImmuPharma Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.01-61.2%
20232023-12-31GBP -0.01-35.7%
20242024-12-31GBP -0.01-25.9%
20252025-12-31GBP -0.00-38.3%
ImmuPharma Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3124.0%
Q22025-06-30N/A
Q32025-09-30100.0%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£6.77K

+85.0%

Gross Margin

0.00%

N/A

Market Cap

£23.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£3.30M

N/A

Employees

7

N/A

Net Income

£31.21K

+103.0%

EBITDA

-£1.30M

-39.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£1.35M

+470.8%

Total Debt

£0.00

N/A

Accounts Receivable

£462.24K

+7.7%

Inventory

£0.00

N/A

Long Term Debt

£0.00

N/A

Short Term Debt

£0.00

N/A

Return on Assets

-96.20%

N/A

Return on Invested Capital

-3.70%

N/A

Free Cash Flow

-£1.37M

-205.4%

Operating Cash Flow

-£1.36M

-205.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SBTX.LSkinBioTherapeutics Plc
£0.12-2.08%
HEMO.LHemogenyx Pharmaceuticals Plc
£6.33-1.17%
POLB.LPoolbeg Pharma PLC
£0.06+1.59%
HVO.LhVIVO plc
£0.08+6.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About IMM

What is the current price of ImmuPharma Plc?

ImmuPharma Plc is trading at £0.04 per share.

What is the 52-week range for ImmuPharma Plc?

Over the past 52 weeks, ImmuPharma Plc has traded between £0.01 and £0.19.

How much debt does ImmuPharma Plc have?

As of the most recent reporting period, ImmuPharma Plc reported total debt of £0.00.

How much cash does ImmuPharma Plc have on hand?

ImmuPharma Plc reported £1.35M in cash and cash equivalents in its most recent financial results.

What is ImmuPharma Plc’s dividend yield?

ImmuPharma Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services